Under the agreement, Lilly will acquire all outstanding shares of
MORF-057 is a selective oral small molecule inhibitor of α4β7 integrin for patients with inflammatory bowel disease (IBD), being developed as Morphic’s lead programme. The molecule is currently in two Phase II studies in ulcerative colitis (UC) and one Phase II study evaluating patients with Crohn’s disease, according to
About the acquisition agreement
“Oral therapies could open up new possibilities for earlier intervention in diseases like ulcerative colitis, and also provide the potential for combination therapy to help patients with more severe disease”
“Oral therapies could open up new possibilities for earlier intervention in diseases like ulcerative colitis, and also provide the potential for combination therapy to help patients with more severe disease,” Dr
The oral small molecule MORF-057 has "the potential to be well tolerated and efficacious, attributes that could unlock new possibilities in IBD treatment… we eagerly anticipate the path forward for MORF-057 and other integrin medicines under Lilly’s stewardship,” commented Dr
Both parties confirmed that the acquisition agreement is not subject to any financing condition. The deal is expected to close in the Q3 2024, subject to customary closing conditions.
Progressing its drug development strategy
The post Lilly agrees
© Russell Publishing Limited, 2024. All Rights Reserved., source